^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CD20 positive

i
Other names: CD20, MS4A1, Membrane Spanning 4-Domains A1, Membrane-Spanning 4-Domains, Subfamily A, Member 1, Leukocyte Surface Antigen Leu-16, B-Lymphocyte Antigen CD20, CD20 Antigen, Membrane-Spanning 4-Domains Subfamily A Member 1, B-Lymphocyte Cell-Surface Antigen B1, B-Lymphocyte Surface Antigen B1, CD20 Receptor, LEU-16, CVID5, MS4A2
Entrez ID:
Related biomarkers:
1d
Case Report: Co-infection with cat-scratch disease and infectious mononucleosis: a rare clinical entity. (PubMed, Front Pediatr)
The diagnosis was based on histopathological features, special stains, and immunohistochemical findings. The coexistence of these two distinct infections highlights the importance of considering multiple etiologies when evaluating reactive lymphadenopathy.
Journal
|
CD20 (Membrane Spanning 4-Domains A1) • TNFRSF8 (TNF Receptor Superfamily Member 8) • CRP (C-reactive protein)
|
CD20 positive • TNFRSF8 positive
1d
Extensive multifocal extranodal diffuse large B-cell lymphoma involving parotid, breast, gastrointestinal tract, and dorsal spine: a case report. (PubMed, Ann Med Surg (Lond))
The patient was given R-CHOP chemotherapy and intrathecal methotrexate with a favorable early response...Image-guided biopsy and immunophenotyping at an early stage are crucial to avoid misdiagnosis and guide appropriate therapy. Individualized and risk-adapted approaches are crucial in maximizing the outcome in such aggressive and rare presentations.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6)
|
CD20 positive
|
Rituxan (rituximab)
6d
Pharmacokinetics of Odronextamab, A Bispecific T-Cell-Engaging Antibody, in Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. (PubMed, CPT Pharmacometrics Syst Pharmacol)
Target-mediated clearance was ~5 L/day at baseline, with an asymptote of ~0.03 L/day at steady state. With the largest covariate effect on odronextamab exposure, baseline body weight was directly correlated with CL and volume of distribution, albumin was inversely correlated with CL and volume of distribution, and baseline interleukin-10 was inversely correlated with CL.
PK/PD data • Journal
|
CD20 (Membrane Spanning 4-Domains A1) • IL10 (Interleukin 10)
|
CD20 positive
|
Ordspono (odronextamab)
9d
Human lysine oxidase-like 3 high expression as a potential biomarker and association with poor prognosis in pleural mesothelioma. (PubMed, Int J Biol Markers)
CD68, CD206, PD-L1, and LOXL3 may collaboratively contribute to the regulation of the PM microenvironment and are closely linked to the invasion and metastasis of PM. Therefore, LOXL3 can be used as both a prognostic marker and a potential therapeutic target for PM.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • WT1 (WT1 Transcription Factor) • IL2 (Interleukin 2) • CD68 (CD68 Molecule) • MRC1 (Mannose Receptor C-Type 1)
|
CD20 positive
14d
Evaluation of CD20-Positive B Cells in Libyan Lymphoma Patients Following Rituximab Treatment. (PubMed, Asian Pac J Cancer Prev)
This study presents flow cytometry-based assessment of Rituximab efficacy in Libyan B cell lymphoma patients, providing novel population-specific data.
Journal
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 positive
|
Rituxan (rituximab)
15d
Efficacy and Limitations of Flow Cytometry for the Rapid Diagnosis of Primary Central Nervous System Lymphoma. (PubMed, Cancers (Basel))
FCM yields reliable diagnostic information within hours of tissue collection and supports early therapeutic decisions in PCNSL. Discordant results may reflect reactive T-cell infiltration. This is the first study to present detailed subset analyses in PCNSL using FCM in correlation with pathology, underscoring its utility as a rapid diagnostic tool.
Journal
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 positive
16d
High-fat diet promotes colorectal tumorigenesis through gut microbiota-mediated metabolic reprogramming and M2 macrophage polarization. (PubMed, Biochem Biophys Res Commun)
HFD induces microbiota-directed metabolic reprogramming and M2 polarization, synergistically accelerating CRC. Notably, targeting key pro-inflammatory taxa (e.g., B. massiliensis) or glycan hydrolysis pathways (e.g. GH95 enzyme) may provide mechanism-guided anti-CRC strategies.
Journal
|
MRC1 (Mannose Receptor C-Type 1)
|
CD20 positive
17d
Clinical and pathological analysis of intravascular large B-cell lymphoma of the prostate. (PubMed, Discov Oncol)
In patients with benign prostate hyperplasia, proliferative blood vessels are found in the interstitium, and there is an accumulation of proliferative large cells in the lumen, which do not resemble endothelial cells, epithelial cells, tissue cells, or inflammatory cells. Pathologists should consider the possibility of intravascular large B-cell lymphoma and conduct immunohistochemical staining for large B-cell lymphoma. Primary intravascular large B-cell lymphoma of the prostate should be diagnosed after ruling out metastatic tumors.
Journal
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 positive
17d
Immune-Mediated Macular Edema After Intravitreal Methotrexate in Primary Vitreoretinal Lymphoma. (PubMed, Ocul Immunol Inflamm)
The simultaneous inversion of the IL-10/IL-6 ratio with edema onset suggests a cytokine shift unmasking an inflammatory response previously suppressed by malignant lymphoproliferation. This pattern supports an immune reconstitution inflammatory syndrome-like mechanism as the most likely cause.
Journal
|
CD20 (Membrane Spanning 4-Domains A1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • IL10 (Interleukin 10) • IL6R (Interleukin 6 receptor)
|
CD20 positive
|
methotrexate
18d
Primary Bone Lymphoma of the Tibia Mimicking Chronic Osteomyelitis: A Case Report. (PubMed, J Orthop Case Rep)
The patient underwent four cycles of R-CHOP chemotherapy...Early tissue biopsy and immunohistochemistry are critical to avoid prolonged misdiagnosis and inappropriate therapy. Clinicians should maintain a high index of suspicion for malignancy in non-resolving bone lesions.
Journal
|
CD20 (Membrane Spanning 4-Domains A1) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C)
|
CD20 positive
|
Rituxan (rituximab)
18d
Primary non-Hodgkin's lymphoma of the right atrium presenting as a cardiac mass: surgical debulking followed by chemotherapy. (PubMed, Indian J Thorac Cardiovasc Surg)
The patient received six cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy with intrathecal methotrexate. This case underscores the importance of including PCL in the differential diagnosis of right atrial masses. Early imaging, prompt tissue diagnosis, and chemotherapy can lead to excellent outcomes even in aggressive disease presentations.
Journal
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 positive
|
Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone
19d
Splenosis involved by in situ follicular B-cell neoplasm. (PubMed, Virchows Arch)
Fluorescence in situ hybridization (FISH) revealed a chromosomal translocation, t(14;18). These findings supported a diagnosis of ISFN.
Journal
|
BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6) • PAX5 (Paired Box 5) • CD5 (CD5 Molecule) • MME (Membrane Metalloendopeptidase)
|
CD20 positive